Xconomy: InDi Unit Looks to Take PET Imaging From Black & White to Technicolor
Summary
InDi Unit Looks to Take PET Imaging ‘From Black & White to Technicolor’ (Page 2 of 2) synthesize a peptide that’s 15 to 16 amino acids long, and that can be built to bind specifically with all kinds of conventional biological targets, such as the prostate-specific antigen (PSA), the HER2 protein that contributes to tumor growth, or any specific portions of a target of interest, Luderer says.Essentially, the diagnostic side of InDi is on track to develop its first commercial product, a blood test for lung cancer, by the end of March 2013.The InDi diagnostics business will be run out of a centralized CLIA-certified lab, but it won’t need to spend the time and money to get an FDA approval like a pharmaceutical company would.Once the InDi Imaging business plan takes shape this fall, the parent company should be able to lay the groundwork for a spinout and separate Series A financing, Luderer says.Drug companies have been showing more interest lately in using advanced imaging technologies to help improve their success rate in the development of new drugs—something that Weston, MA-based Biogen Idec (NASDAQ: BIIB) talked about yesterday with investors in its annual R&D day.